Original Research

Saving money in the European healthcare systems with biosimilars

Published in: Volume 1 / Year 2012 / Issue 3-4
Author(s): , , ,
Page: 120-6

Introduction: The use of biotechnological manufactured drugs, or biologicals, has increased massively over the past few years. Used especially in the treatment of cancer and other severe diseases, biologicals incur high… Read More »

Biosimilars for Healthcare Professionals

Author(s):

Read More »

One-day out-patient prescribing patterns including the use of generics at a national referral hospital in Kenya; implications for the future

Author(s): , , , , ,

Background: Poor prescribing habits lead to ineffective and unsafe treatment for patients, exacerbating or prolonging of illness as well as causing distress and harm to them. Drug utilization studies can… Read More »

Extended stability study of a biosimilar of trastuzumab (CT-P6) after reconstitution in vials and after dilution in polyolefin bags and storage at fridge and room temperature

Author(s): , ,

Abstract: The long-term stability of CT-P6 biosimilar trastuzumab (Herzuma®, Biogaran Laboratories) has been studied in their vials after reconstitution of the lyophilized powder (21 mg/mL) and after dilution for final… Read More »

Building trust on biosimilars: Continuous safety surveillance of a biosimilar Bevacizumab (BEVAX®) in Argentina

Author(s): , , , , ,

Abstract: Introduction and study objectives: The evaluation of the benefit-risk ratio of a drug is essential throughout its whole life cycle to guarantee that therapeutic efficacy for the authorized indications… Read More »

Page 4 of 4 « Previous1 2 3 4
Go Back Print